Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin - XML Representation

Raw xml | Download


<Group xmlns="http://hl7.org/fhir">
  <id value="179786"/>
  <meta>
    <versionId value="3"/>
    <lastUpdated value="2023-12-04T20:30:40.963Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-definition"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Group 179786</b></p><a name="179786"> </a><a name="hc179786"> </a><a name="179786-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 3; Last updated: 2023-12-04 20:30:40+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-exposure-definition.html">ExposureDefinition</a></p></div><p><b>Artifact related artifact</b>: No display for RelatedArtifact  (type: cite-as; citation: ExposureDefinition: Therapeutic-dose anticoagulation with heparin [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179786. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179786. Computable resource at: https://fevir.net/resources/Group/179786.)</p><p><b>Artifact Title</b>: ExposureDefinition: Therapeutic-dose anticoagulation with heparin</p><p><b>Artifact URL</b>: <a href="https://fevir.net/resources/Group/179786">https://fevir.net/resources/Group/179786</a></p><p><b>Artifact Publisher</b>: Computable Publishing LLC</p><p><b>Artifact Copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>Artifact Contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>org/fhir/uv/ebm/StructureDefinition/combination-method</b>: any-of</p><p><b>Artifact Status</b>: active</p><p><b>identifier</b>: FEvIR Object Identifier/179786</p><p><b>name</b>: ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin</p><p><b>description</b>: </p><div><p>Description: therapeutic-dose anticoagulation with heparin
Note: Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours.</p>
</div><p><b>type</b>: Animal</p><p><b>membership</b>: Definitional</p><blockquote><p><b>characteristic</b></p><p><b>org/fhir/uv/ebm/StructureDefinition/characteristic-description</b>: </p><div><p>ATTACC investigational arm</p>
</div><blockquote><p><b>CharacteristicTiming</b></p><ul><li>contextCode: <span title="Codes:">Start of trial</span></li><li>offset: 0-14</li><li>text: Up to 14 days or until hospital discharge or recovery (defined as liberation from supplemental oxygen&gt;24 hours, provided oxygen was required), whichever comes first.</li></ul></blockquote><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels.</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>org/fhir/uv/ebm/StructureDefinition/characteristic-description</b>: </p><div><p>ACTIV-4a investigational arm</p>
</div><blockquote><p><b>CharacteristicTiming</b></p><ul><li>contextCode: <span title="Codes:">Start of trial</span></li><li>offset: 0-14</li><li>text: Up to 14 days or until hospital discharge, whichever comes first.</li></ul></blockquote><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal.</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>org/fhir/uv/ebm/StructureDefinition/characteristic-description</b>: </p><div><p>REMAP-CAP investigational arm</p>
</div><blockquote><p><b>CharacteristicTiming</b></p><ul><li>contextCode: <span title="Codes:">Start of trial</span></li><li>offset: 0-14</li><li>text: Up to 14 days or until hospital discharge, whichever comes first.</li></ul></blockquote><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels.</span></p><p><b>exclude</b>: false</p></blockquote></div>
  </text>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
    <valueRelatedArtifact>
      <type value="cite-as"/>
      <citation
                value="ExposureDefinition: Therapeutic-dose anticoagulation with heparin [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179786. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179786. Computable resource at: https://fevir.net/resources/Group/179786."/>
    </valueRelatedArtifact>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-title">
    <valueString
                 value="ExposureDefinition: Therapeutic-dose anticoagulation with heparin"/>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-url">
    <valueUri value="https://fevir.net/resources/Group/179786"/>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-publisher">
    <valueString value="Computable Publishing LLC"/>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-copyright">
    <valueMarkdown
                   value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-contact">
    <valueContactDetail>
      <telecom>
        <system value="email"/>
        <value value="support@computablepublishing.com"/>
      </telecom>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name value="Brian S. Alper"/>
    </valueContactDetail>
  </extension>
  <extension
             url="http://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method">
    <valueCode value="any-of"/>
  </extension>
  <modifierExtension
                     url="http://hl7.org/fhir/StructureDefinition/artifact-status">
    <valueCode value="active"/>
  </modifierExtension>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net"/>
    <value value="179786"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <name
        value="ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin"/>
  <description
               value="Description: therapeutic-dose anticoagulation with heparin
Note: Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours."/>
  <type value="animal"/>
  <membership value="definitional"/>
  <characteristic>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
      <valueMarkdown value="ATTACC investigational arm"/>
    </extension>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing">
      <extension url="contextCode">
        <valueCodeableConcept>
          <text value="Start of trial"/>
        </valueCodeableConcept>
      </extension>
      <extension url="offset">
        <valueRange>
          <low>
            <value value="0"/>
          </low>
          <high>
            <value value="14"/>
            <unit value="days"/>
            <system value="http://unitsofmeasure.org"/>
            <code value="d"/>
          </high>
        </valueRange>
      </extension>
      <extension url="text">
        <valueString
                     value="Up to 14 days or until hospital discharge or recovery (defined as liberation from supplemental oxygen&gt;24 hours, provided oxygen was required), whichever comes first."/>
      </extension>
    </extension>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels."/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
      <valueMarkdown value="ACTIV-4a investigational arm"/>
    </extension>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing">
      <extension url="contextCode">
        <valueCodeableConcept>
          <text value="Start of trial"/>
        </valueCodeableConcept>
      </extension>
      <extension url="offset">
        <valueRange>
          <low>
            <value value="0"/>
          </low>
          <high>
            <value value="14"/>
            <unit value="days"/>
            <system value="http://unitsofmeasure.org"/>
            <code value="d"/>
          </high>
        </valueRange>
      </extension>
      <extension url="text">
        <valueString
                     value="Up to 14 days or until hospital discharge, whichever comes first."/>
      </extension>
    </extension>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal."/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
      <valueMarkdown value="REMAP-CAP investigational arm"/>
    </extension>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing">
      <extension url="contextCode">
        <valueCodeableConcept>
          <text value="Start of trial"/>
        </valueCodeableConcept>
      </extension>
      <extension url="offset">
        <valueRange>
          <low>
            <value value="0"/>
          </low>
          <high>
            <value value="14"/>
            <unit value="days"/>
            <system value="http://unitsofmeasure.org"/>
            <code value="d"/>
          </high>
        </valueRange>
      </extension>
      <extension url="text">
        <valueString
                     value="Up to 14 days or until hospital discharge, whichever comes first."/>
      </extension>
    </extension>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels."/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
</Group>